Tysabri

Tysabri. It is a monoclonal antibody medication used primarily in the treatment of multiple sclerosis and Crohn's disease. Developed by Biogen and initially approved by the U.S. Food and Drug Administration in 2004, it is administered via intravenous infusion. Its use is often reserved for patients who have had an inadequate response to, or cannot tolerate, other available therapies due to significant associated risks.

Medical uses

Tysabri is indicated for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. In the United States, it is also approved for the treatment of moderate to severe Crohn's disease in adults who have demonstrated an inadequate response to conventional therapies, including inhibitors of tumor necrosis factor. Treatment typically involves infusion every four weeks at an approved infusion center, and its use is often governed by a restricted distribution program called the TOUCH Prescribing Program to mitigate specific risks. Clinical trials, such as the AFFIRM trial, demonstrated its efficacy in reducing the rate of clinical relapses and the development of new brain lesions as seen on magnetic resonance imaging.

Adverse effects

The most serious adverse effect associated with Tysabri is the risk of developing progressive multifocal leukoencephalopathy, a rare and often fatal viral infection of the brain caused by the JC virus. This risk is significantly higher in patients who are positive for JC virus antibodies, have received immunosuppressant therapies like mitoxantrone or azathioprine, and have a longer duration of treatment, particularly beyond two years. Other potential adverse reactions include hypersensitivity reactions, such as urticaria and anaphylaxis, as well as more common infusion-related reactions. Patients may also experience hepatotoxicity, and infections such as herpes encephalitis and meningitis have been reported in clinical studies and post-marketing surveillance.

Mechanism of action

Tysabri functions as a selective adhesion-molecule inhibitor, specifically targeting the alpha-4 subunit of integrin proteins found on the surface of leukocytes. By binding to alpha-4 beta-1 integrin and alpha-4 beta-7 integrin, the drug inhibits the adhesion of these immune cells to their corresponding receptors, such as vascular cell adhesion molecule-1 and mucosal addressin cell adhesion molecule-1. This blockade prevents the transmigration of lymphocytes across the blood–brain barrier into the central nervous system parenchyma, thereby reducing the inflammatory damage characteristic of multiple sclerosis. In Crohn's disease, a similar mechanism is believed to inhibit lymphocyte migration into the inflamed intestinal tissues.

History

Tysabri was developed by the biotechnology company Biogen (now Biogen Idec) and received its first approval from the U.S. Food and Drug Administration in November 2004 for the treatment of multiple sclerosis. In February 2005, it was voluntarily withdrawn from the market by Biogen and its co-marketing partner Élan following reports of several cases of progressive multifocal leukoencephalopathy, including two fatalities. After a comprehensive safety review and the establishment of a stringent risk management plan, the FDA allowed its reintroduction in July 2006 under a restricted distribution program. Subsequent approvals by the European Medicines Agency and regulatory bodies worldwide followed, with its indication later expanded to include Crohn's disease in many regions.

Society and culture

The reintroduction of Tysabri under the TOUCH Prescribing Program established a new paradigm for risk management and pharmacovigilance in the pharmaceutical industry. Its history has been a significant topic in discussions of drug safety, leading to increased scrutiny by the FDA and the European Medicines Agency for other biologic therapies. The drug has been the subject of notable legal cases and settlements, including litigation related to cases of progressive multifocal leukoencephalopathy. Patient advocacy groups, such as the National Multiple Sclerosis Society, have provided extensive educational resources regarding its risks and benefits, influencing treatment decisions within the neurology and gastroenterology communities. Category:Monoclonal antibodies Category:Multiple sclerosis medications Category:Biogen